Finally, some data.
Here is where Azer-cel + chemotherapy compares to some of the other Allogeneic CAR-T therapies in combination with chemotherapy.
In comparison to peer allogeneic CAR T therapies, Azer-cel appears to be underperrforming as well as lagging behind in clinical development. With so many competitors, the risk of clinical and moreso commercial success is very high.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00554-0/fulltext
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7025
https://www.sciencedirect.com/science/article/pii/S0006497121022990
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32334-5/abstract
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2517
https://www.nature.com/articles/s41591-023-02785-8
Ann: Three Complete Responses in Azer-Cel Phase 1b Trial, page-120
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
0.007(11.3%) |
Mkt cap ! $507.0M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 8.1¢ | 6.7¢ | $13.21M | 174.6M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1746163 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 312504 | 9 |
View Market Depth
| Last trade - 13.50pm 02/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |